Fig. 2: Effect of R2 vaccination by intramuscular (IM), intradermal (ID), and intravaginal (IVag) routes on acute disease following vaginal HSV-2 challenge. | npj Vaccines

Fig. 2: Effect of R2 vaccination by intramuscular (IM), intradermal (ID), and intravaginal (IVag) routes on acute disease following vaginal HSV-2 challenge.

From: The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model

Fig. 2

A The severity of acute disease (0–14 dpi) following intravaginal challenge with 1 × 106 pfu of HSV-2 (MS Strain). IM vaccination with gD+MPL/Alum is included as a positive control. The severity of the acute disease was quantified using a score-scale ranging from 0 to 4. Error bars are standard deviation. B The percent of animals that developed acute genital lesions. The number of animals is indicated above each bar. C Replication of HSV-2 in the vaginal tract during the week after vaginal challenge. Animals were swabbed on days 2, 4, and 8 after challenge and shedding quantified by plaque titration. The numbers above the columns indicate the number of animals with the detectable virus. Bars are the Log10 GMT. Error bars are standard deviation. The dotted line indicates the level of detection. a P < 0.001 vs. No Vaccine, b P < 0.05 vs.R2 IM, c P < 0.05 vs. No Vaccine, d P < 0.05 vs R2 IVag e P < 0.05 vs. gD + MPL/Alum.

Back to article page